Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients

Lung Cancer

Volumn 67, Issue 1, 2010, Pages 101-107

  Takenaka, Tomoyoshi ^a   Yano, Tokujiro ^a   Kiyohara, Chikako ^a   Miura, Naoko ^a   Kouso, Hidenori ^a   Ohba, Taro ^a   Kometani, Takuro ^a   Shoji, Fumihiro ^a   Yoshino, Ichiro ^b   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Chemosensitivity; Excision repair cross complementation group 1; Non small cell lung cancer; Prognosis; Single nucleotide polymorphism

Indexed keywords

ADENOSINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTIDINE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; THYMIDINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG SENSITIVITY; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; JAPANESE; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 71549134934     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.03.007     Document Type: Article

References (29)

1. De Laat W.L., Appeldoorn E., Jaspers N.G., and Hoeijmakers J.H. DNA structural elements required for ERCC1-XPF endonuclease activity. J Biol Chem 273 (1998) 7835-7842
2. Sijbers A.M., de Laat W.L., Ariza R.R., Biggerstaff M., Wei Y.F., Moggs J.G., et al. Xeroderma pigmentosum Group F caused by a defect in a structure-specific DNA repair endonuclease. Cell 86 (1996) 811-822
3. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25 (2007) 2747-2754
4. Smith S., Su D., Rigault de la Longrais I.A., Schwartz P., Puopolo M., Rutherford T.J., et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 25 (2007) 5172-5179
5. Britten R.A., Liu D., Tessier A., Hutchison M.J., and Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 89 (2000) 453-457
6. Shirota Y., Stoehlmacher J., Brabender J., Xiong Y.P., Uetake H., Danenberg K.D., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracilchemotherapy. J Clin Oncol 19 (2001) 4298-4304
7. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression Correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8 (2002) 2286-2291
8. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., and Vansteenkiste J. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
9. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006) 983-991
10. Chen P., Wiencke J., Aldape K., Kesler-Diaz A., Miike R., Kelsey K., et al. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 9 (2000) 843-847
11. Zienolddiny S., Campa D., Lind H., Ryberg D., Skaug V., Stangeland L., et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 27 (2006) 560-567
12. Zhou W., Liu G., Park S., Wang Z., Wain J.C., Lynch T.J., et al. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 491-496
13. Yu J.J., Lee K.B., Mu C., Li Q., Abernathy T.V., Bostick-Bruton F., et al. Comparison of two human ovarian carcinoma cell line (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16 (2000) 555-560
14. Viguier J., Boige V., Miquel C., Pocard M., Giraudeau B., Sabourin J.C., et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 17 (2005) 6212-6217
15. Smith S., Su D., Rigault de la Longrais I.A., Schwartz P., Puopolo M., Rutherford T.J., et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 33 (2007) 5172-5179
16. Isla D., Sarries C., Rosell R., Alonso G., Domine M., Taron M., et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 8 (2004) 1194-1203
17. Zhou W., Gurubhagavatula S., Liu G., Park S., Neuberg D.S., Wain J.C., et al. Excision repair cross -complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10 (2004) 4939-4943
18. Suk R., Gurubhagavatula S., Park S., Zhou W., Su L., Lynch T.J., et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 11 (2005) 1534-1538
19. World Health Organization. Histological typing of lung and pleural tumors. 3rd edn. (1999), Springer-Verlag, Geneva, Switzerland
20. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
21. Egashira A., Morita M., Kakeji Y., Sadanaga N., Oki E., Honbo T., et al. p53 gene mutations in esophageal squamous cell carcinoma and their relevance to etiology and pathogenesis: results in Japan and comparisons with other countries. Cancer Sci 98 (2007) 1152-1156
22. Yin J., Vogel U., Guo L., Ma Y., and Wang H. Lack of association between DNA repair gene ERCC1 polymorphism and risk of lung cancer in a Chinese population. Cancer Genet Cytogenet 164 (2006) 66-70
23. Takenaka T., Yoshino I., Kouso H., Ohba T., Yohena T., Osoegawa A., et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 121 (2007) 895-900
24. Oki E., Baba H., Tokunaga E., Nakamura T., Ueda N., Futatsugi M., et al. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 117 (2005) 376-380
25. Asanuma F., Yamada Y., Kawamura E., Kurokawa T., Lee K.E., Yamada T., et al. Comparison between clinical response and in vitro chemosensitivity of solid tumors in the succinic dehydrogenase inhibition test. Gan To Kagaku Ryoho 19 (1992) 95-101
26. Kimura H., Yonemura Y., Ohyama S., Tsugawa K., Kinoshita K., Ninomiya I., et al. The succinate dehydrogenase inhibition test for evaluating biopsy specimens and resected tumors of advanced gastric cancer. Surg Today 22 (1992) 508-511
27. Su D., Ma S., Liu P., Jiang Z., Lv W., Zhang Y., et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 56 (2007) 281-288
28. Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., and Gottesman M.M. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315 (2007) 525-528
29. Kato H., Ichinose Y., Ohta M., Hata E., Tsubota N., Tada H., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 (2004) 1713-1721